Literature DB >> 31953112

Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.

Lindsey Alley1, Kevin Novak1, Tyler Havlin1, Adriane N Irwin2, Jody Carson1, Kirbee Johnston2, Nicole O'Kane1, Daniel M Hartung3.   

Abstract

BACKGROUND: Pharmacists' role in addressing the opioid crisis continues to expand, but lack of training specifically related to standardized prescription drug monitoring program (PDMP) use and communication strategies for provider and patient interactions remains a significant issue. We developed the Resources Encouraging Safe Prescription Opioid and Naloxone Dispensing (RESPOND) Toolkit to enhance community pharmacists' understanding of their role in addressing opioid safety; improve integration of PDMP into daily workflow; and enhance communication between pharmacists, prescribers, and patients.
OBJECTIVE: To describe the development of RESPOND Toolkit and summarize findings from initial pilot testing.
METHODS: RESPOND development was informed by focus groups with patients, prescribers, and pharmacists and an external advisory committee. Materials developed include a patient screening & communication algorithm, a provider communication checklist and an online continuing education course with three distinct modules. The RESPOND Toolkit was pilot tested in six community pharmacies in Oregon across two 6-month intervention phases. Pilot data collection included a pre-post intervention survey, pre-post knowledge assessment quizzes within the online course, and post-intervention semi-structured interviews. Interview feedback informed revisions after each phase to shape the final content, flow, and delivery of RESPOND.
RESULTS: Sixteen of 21 pharmacists completed the online training, revealing a large, significant effect on knowledge gain across the three training modules (pre-score 57, post-score 84; p < 0.001; Cohen's d = 1.85). Of these participants, 10 also completed the baseline and post intervention survey and showed non-significant moderate improvements in knowledge, perceived behavioral control, and self-efficacy to address opioid safety issues.
CONCLUSION: The RESPOND Toolkit has promise as an effective and scalable approach to providing community pharmacist-tailored training, especially in the areas of effective communication and workflow integration, to promote behavioral shifts supporting opioid safety for patients. Further development and testing in a larger sample is warranted.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Communication; Community pharmacist; Opioid safety; PDMP; Toolkit; Training

Mesh:

Substances:

Year:  2020        PMID: 31953112     DOI: 10.1016/j.sapharm.2019.12.023

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  5 in total

Review 1.  Evaluations of Continuing Health Provider Education Focused on Opioid Prescribing: A Scoping Review.

Authors:  Abhimanyu Sud; Graziella R Molska; Fabio Salamanca-Buentello
Journal:  Acad Med       Date:  2022-02-01       Impact factor: 7.840

Review 2.  Optimization of Prescription Drug Monitoring Program to Overcome Opioid Epidemic in West Virginia.

Authors:  Ala-Eddin Yassin Al-Astal; Komal Sodhi; Hari Vishal Lakhani
Journal:  Cureus       Date:  2022-02-21

3.  Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) Online Continuing Education Program: A Randomized Controlled Trial.

Authors:  Ashley Cid; Alec Patten; Michael Beazely; Kelly Grindrod; Jennifer Yessis; Feng Chang
Journal:  Pharmacy (Basel)       Date:  2022-02-04

4.  Pharmacists' perceptions on real-time prescription monitoring (RTPM) systems - a cross-sectional survey.

Authors:  Ziyue Zhang; Lin Guo; Ran Si; Leanne Chalmers; Patricia Filippin; Jane Carpenter; Petra Czarniak
Journal:  Explor Res Clin Soc Pharm       Date:  2022-03-02

5.  Development and evaluation of an online training program based on the O-AMAS teaching model for community pharmacists in the post-COVID-19 era.

Authors:  Bingzheng Shen; Jun Liu; Jiahuan Helen He; Zhanyong Zhu; Benhong Zhou
Journal:  Front Public Health       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.